Small capRs 1,534 crRs 1.6 cr traded a dayThin: a ₹2 lakh order is 1.2% of a normal day
Close on 10 September 2026
232.99
−1.02%
52-week range88% of the way up
161.07243.02
Market cap
1,534 cr
P/E (TTM)
33.7×
EPS (TTM)
6.91
Revenue YoY
+8.8%
Q1 FY27
Profit YoY
+22.2%
Net margin
16.0%
+1.8pt vs a year ago
Growth trend
-0.9pt
vs last quarter’s YoY
1 month
+3.3%
Below 52w high
4.3%
RSI (14)
45
Daily swing
3.5%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 2 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Above the median
+14.9%
One-year return
Around the median
-2.0%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+8.8%
Below the 52-week high
from the highest close of the year
-4.1%
1 week
−4.13%
1 month
+3.34%
3 months
+9.33%
6 months
+25.72%
1 year
−2.02%
The read
written from the numbers on this page
The evidence leans constructive6 supporting, 3 against, 0 worth knowing
Supporting
trading 15% above its 200-day average
sitting at 88% of its 52-week range, with little overhead supply from trapped buyers
matches the market's strongest stocks, which has beaten the market by +0.59 points over 20 sessions across 51,498 past signals
3 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 9% year on year in the quarter ending 30 June 2026
Against
down 2% over twelve months
1 of the scans it matches has historically underperformed the market
net margin has narrowed from 16.9% to 16.0% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close below 203, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working6
Net profit +22.2% year on year, Rs 11 cr to Rs 13 cr.
+22.2%Rs 11 crRs 13 cr
Net margin moved from 14.3% to 16.0%.
14.3%16.0%
Profit grew faster than revenue, +22.2% against +8.8%.
+22.2%+8.8%
Trading 14.9% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+14.9%
Turned up over three months while the year is still negative.
+9.3% 3M-2.0% 1Y
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching1
Only Rs 1.6 crore changes hands on a median day. A large order moves this price by itself.
Rs 1.6 cr
Every figure here is computed — from the company’s own filings, or from its own closing prices. The wording is generated directly from the figures.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
6 of 47 matched on 10 Sep
JAGSNPHARM matches 6 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
JAGSNPHARM trades at 34× trailing earnings, above its median of 28× over this window — 21% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 9% against the same quarter a year earlier
profit rose 22% year on year
net margin widened from 13.6% to 16.0%
Going against it
revenue rose in 1 of the last 4 quarters
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · standalone
82
18
13
2.00
16.0%
Q4 FY26
31 Mar · standalone
64
12
9
1.25
13.6%
Q3 FY26
31 Dec · standalone
73
15
11
1.67
15.0%
Q2 FY26
30 Sep · standalone
74
17
13
1.88
16.9%
Q1 FY26
30 Jun · standalone
76
14
11
1.60
14.3%
Q4 FY25
31 Mar · standalone
59
9
7
0.98
11.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+0.2%
Versus 200-day average+14.9%
Below 52-week high-4.1%
Above 52-week low+44.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)44.9
Higher closes in last 50 of 5
Six-month return+25.72%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.